Intradermal injection of Newcastle disease virus-modified autologous melanoma cell lysate and interleukin-2 for adjuvant treatment of melanoma patients with resectable stage III disease

JDDG - Journal of the German Society of Dermatology

Volumn 1, Issue 2, 2003, Pages 120-125

  Voit, Christiane ^a   Kron, Martina ^b   Schwürzer Voit, Markus ^a   Sterry, Wolfram ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

Adjuvants, immunological; Cancer vaccines; Disease free survival; Immunotherapy, active; Melanoma; Trial; Vaccination

Indexed keywords

INTERLEUKIN 2; PLACEBO; TUMOR CELL VACCINE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURVIVAL; CELL LYSATE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; DRUG SCREENING; FOLLOW UP; HUMAN; MELANOMA; MELANOMA CELL; NEWCASTLE DISEASE PARAMYXOVIRUS; POSTOPERATIVE CARE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT FAILURE; VACCINATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; GERMANY; HUMANS; INJECTIONS, INTRADERMAL; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; ONCOLYTIC VIROTHERAPY; PLACEBO EFFECT; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SKIN NEOPLASMS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; VIRAL VACCINES;

EID: 0038222327     PISSN: 16100379     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1610-0387.2003.02014.x     Document Type: Article

References (21)

1. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7-17.
2. Legha SS. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy. Semin Oncol 1997; 24: S39-S43.
3. Czarnetzki BM, Macher E, Suciu S, Thomas D, Steerenberg PA, Rumke P. Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC Protocol 18781). Eur J Cancer 1993; 29A: 1237-1242.
4. Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 1998; 187: 69-77.
5. Elliott GT, McLeod RA, Perez J, Von Eschen KB. Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma. Semin Surg Oncol 1993; 9: 264-272.
6. Morton DL, Foshag LJ, Hoon DS, Nizze JA, Famatiga E, Wanek LA et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992; 216: 463-482.
7. Berd D, Maguire HC Jr, McCue P, Mastrangelo MJ. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol 1990; 8: 1858-1867.
8. Schirrmacher V, Heicappell R. Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. II. Establishment of specific systemic anti-tumor immunity. Clin Exp Metastasis 1987; 5: 147-156.
9. Von Hoegen P, Zawatzky R, Schirrmacher V. Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor-specific cytolytic T cell activity via induction of interferon-alpha/beta. Cell Immunol 1990; 126: 80-90.
10. Ahlert T, Schirrmacher V. Isolation of a human melanoma adapted Newcastle disease virus mutant with highly selective replication patterns. Cancer Res 1990; 50: 5962-5968.
11. Schirrmacher V, Griesbach A, Ahlert T. Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects. Int J Oncol 2001; 18: 945-952.
12. Schlag P, Manasterski M, Gerneth T, Hohenberger P, Dueck M, Herfarth C et al. Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II trial. Cancer Immunol Immunother 1992; 35: 325-330.
13. Vermorken JB, Claessen AM, van Tinteren H, Gall HE, Ezinga R, Meijer S et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 1999; 353: 345-350.
14. Harris JE, Ryan L, Hoover HC Jr, Stuart RK, Oken MM, Benson AB III et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol 2000; 18: 148-157.
15. Voit C, Mayer T, Proebstle TM, Weber L, Kron M, Krupienski M et al. Ultrasound-guided fine-needle aspiration cytology in the early detection of melanoma metastases. Cancer 2000; 90: 186-193.
16. Washburn B, Schirrmacher V. Human tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis. Int J Oncol 2002; 21: 85-93.
17. Zeng J, Fournier P, Schirrmacher V. Induction of interferon-alpha and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus. Virology 2002; 297: 19-30.
18. Cassel WA, Murray DR. A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Med Oncol Tumor Pharmacother 1992; 9: 169-171.
19. Batliwalla FM, Bateman BA, Serrano D, Murray D, Macphail S, Maino VC et al. A 15-year followup of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire. Mol Med 1998; 4: 783-794.
20. Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 2002; 20: 1818-1825.
21. Csatary LK, Moss RW, Beuth J, Torocsik B, Szeberenyi J, Bakacs T. Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H). Anticancer Res 1999; 19: 635-638.